Results 141 to 150 of about 701,268 (244)

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Peripheral blood eosinophil count for predicting progression-free survival in non-small cell lung cancer: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Chen W, Ding G.
europepmc   +1 more source

PRM155 - JOINT MODELING OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL [PDF]

Value in Health, 2018
F Felizzi, I Bennett, M Pletscher, P Thuresson, N Paracha, J Ray   +5 more
openaire   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Salvage surgery following primary treatment in recurrent vestibular schwannoma: surgical outcomes and progression-free survival- a meta-analysis. [PDF]

J Neurooncol
Haddad L, Arlt F, Güresir E, Wach J.
europepmc   +1 more source

PRM12 Joint Estimation of Progression Free Survival and Overall Survival [PDF]

Value in Health, 2012
Ouwens, M.J., Bergman, G.
openaire   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Disturbance of functional connectivity in patients with low grade glioma is associated with worse progression-free survival. [PDF]

Neurooncol Adv
Stoecklein VM, Wunderlich S, Weller J, Papazov B, Suvak S, Katzendobler S, Schmutzer-Sondergeld M, Schichor C, Thon N, Von Baumgarten L, Kalasauskas D, Harter PN, Ricke J, Liebig T, Ringel F, Stoecklein S.   +15 more
europepmc   +1 more source

Progression-free or overall survival…revisited in BOLERO-2 [PDF]

Indian Journal of Medical and Paediatric Oncology, 2014
openaire   +3 more sources

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source